Press

  • aside

    FDA CLEARS ISOFOL’S IND APPLICATION TO START CLINICAL PROGRAM WITHIN COLORECTAL CANCER WITH MODUFOLIN®

    Isofol Medical AB announces that the US Food and Drug Administration (FDA) has cleared Isofol’s investigational new drug (IND) application…

    by
  • aside

    Isofol Medical present at Aktietorget investor meeting

    Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting arranged by SvD…

    by
  • aside

    Isofol Medical has successfully advanced to the next dose level of Modufolin® in a phase I/II clinical trial in colorectal cancer.

    Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or…

    by
  • aside

    Isofol announces successful meetings with European and US regulatory authorities regarding the design of a pivotal Phase II clinical trial of Isofol’s lead Drug candidate, Modufolin®

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology is pleased with the…

    by
  • aside

    Isofol Medical share issue oversubscribed, securing over SEK 39 million to strengthen the ongoing Phase II clinical development program of Modufolin®

    Isofol Medical AB, a clinical stage pharmaceutical company, developing novel products for unmet needs within oncology, will use the investment…

    by
  • aside

    Isofol successfully completes first dose cohort with Modufolin® as a rescue therapy in osteosarcoma patients after high dose methotrexate (HDMTX) treatment

    Isofol Medical AB today announced that the first dose cohort with Modufolin® as rescue therapy, after treatment with two cycles…

    by